Telemedics
Prix: 72.91Entreprise et modèle économique
Telemedics (TMDX.US) operates in the healthcare sector, focusing on advanced telemedicine solutions. Its core products include remote patient monitoring systems and digital health platforms that facilitate virtual consultations and data analytics. The company generates revenue primarily through subscription services and software licensing, catering to healthcare providers and patients.
Profil d’investissement
The investment profile of Telemedics is more aligned with balanced investors, given its moderate growth potential and current market position. The absence of dividends and the high risk associated with its operations suggest a cautious approach. The stock may appeal to those looking for a mix of growth and stability over a medium to long-term horizon.
Métriques fondamentales (expérimental)
- BPA (TTM) — bénéfice par action des 12 derniers mois, $
- 5.03 OK
- Chiffre d’affaires QoQ — croissance trimestrielle du chiffre d’affaires
- 8.2% ↑
- Surprise BPA
- -51.6% moins bon que prévu
- Volatilité 20 j
- 2.8% stable
Impact de la prévision
neutreSuivre dans le portefeuille
Graphique des prix
| Date | Avant | Après | Raison |
|---|---|---|---|
| 2026-06-03 02:54 | Conserver | Vendre | Weak fundamentals and negative momentum indicate high risk. |
| 2026-05-08 15:07 | — | Conserver | Weak momentum and high risk overshadow potential growth. |
| 2026-05-08 05:33 | Conserver | Conserver | Компания демонстрирует значительное снижение цен на акции за последние месяцы, что указывает на высокие риски. Несмотря на положительные показатели EPS и рост выручки, текущая динамика цен не внушает доверия. |
| Date | Analyste | Action | Objectif | Prix alors |
|---|---|---|---|---|
| 2026-05-26 10:50 | Stifel Nicolaus | Objectif abaissé | 85 → 75 | 68.935 |
| 2026-05-06 13:42 | Needham | Objectif abaissé | 174 → 142 | 73.8351 |
| 2026-05-06 11:46 | Canaccord Genuity | Objectif abaissé | 152 → 124 | 94.93 |
Rien pour le moment